PET/CT Bests Biopsy in Lymphoma Progression to Bone Marrow
18F-FDG PET/CT can better assess bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma than can standard bone biopsy.
Examination with 18F-FDG PET/CT can better determine the level of bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) than can bone marrow biopsy, according to a study published in The Journal of Nuclear Medicine.
French researchers performed a retrospective study of 133 patients diagnosed with DLBCL between June 2005 and October 2011. To determine if there was bone marrow involvement, all the patients underwent whole-body 18F-FDG PET/CT and a bone marrow biopsy from the iliac crest before any treatment. Median follow-up was 24 months, ranging from one to 67 months.
A final diagnosis of bone marrow involvement was made if the biopsy was positive, or if the positive PET/CT scan was confirmed by a guided biopsy, by targeted MRI or, after chemotherapy, by the concomitant disappearance of focal bone marrow uptake and uptake in other lymphoma lesions on 18F-FDG PET/CT reassessment. Progression-free survival and overall survival were then analyzed.
The results showed that 33 patients were considered to have bone marrow involvement, eight of whom were positive according to the biopsy. Thirty-two were positive according to the PET/CT scan.
The 18F-FDG PET/CT was more sensitive (94 percent versus 24 percent), showed a higher negative predictive value (98 percent versus 80 percent), and was more accurate (98 percent versus 81 percent) than was the biopsy. Twenty-nine patients (22 percent) experienced recurrence or disease progression during follow-up and 20 patients died (15 percent).
Among the 26 patients with positive 18F-FDG PET/CT results and negative biopsy results, 11 were upstaged to stage IV by PET/CT, which changed their treatment plans. 18F-FDG PET/CT was also determined to be an independent predictor of progression-free survival.
The researchers concluded that bone marrow involvement assessed with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification in newly diagnosed DLBCL than does bone marrow biopsy.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
